Skip to Main Content

Paper Details

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Am J Hematol
0
2024
Author NameAffiliation
Elie TraerOregon Health & Science University
Guillermo Garcia-ManeroMD Anderson Cancer Center
David P SteensmaNovartis Institutes for BioMedical Research
Uma BorateOregon Health & Science University
  • 1 - 4

Datasets

Release 1.2